skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15370

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy



Review

(7503) Total Article Views


Authors: Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò, et al

Published Date February 2011 Volume 2011:3 Pages 37 - 46
DOI: http://dx.doi.org/10.2147/CEOR.S16655

Giorgio L Colombo1,2, Giovanni B Gaeta3, Mauro Viganò4, Sergio Di Matteo2
1University of Pavia, School of Pharmacy, Italy; 2S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy; 3Viral Hepatitis Unit, Second University, Naples, Italy; 4Liver Unit, Ospedale San Giuseppe, Università degli Studi di Milano, Milan, Italy

Introduction: Chronic hepatitis B (CHB) is a prevalent disease associated with high morbidity, mortality, and impact on health care costs. Antiviral therapy is aimed at reducing hepatitis B virus replication in order to limit progressive liver disease and improve the natural history of the disease. This study estimates the cost-effectiveness of lamivudine, adefovir, telbivudine, entecavir, tenofovir, and pegylated interferon in patients with CHB.
Methods: A Markov model was developed to evaluate the costs and benefits of antivirals in a cohort of patients with CHB (hepatitis B e antigen [HBeAg]-positive and HBeAg-negative) and cirrhosis over a period of 10 years. Different rescue therapies were considered, according to current guidelines. Data on efficacy and changes in quality of life were derived from clinical trials and epidemiological Italian data. Direct costs were assessed from the perspective of the Italian National Health Service.
Results: Tenofovir was associated with lower costs and higher efficacy compared with entecavir, telbivudine, and adefovir, as shown by their incremental cost-effectiveness ratios (ICER) per quality-adjusted life-year (QALY) gained: tenofovir €30,959, entecavir €45,971, telbivudine €62,051, and adefovir €82,824. Even following 1 year of pegylated interferon therapy, tenofovir had a more favourable ICER per QALY gained compared with the other rescue options. The analysis of patients with cirrhosis confirms the results obtained with the CHB cohort though with higher ICERs. Sensitivity analyses on the main variables confirm the results of the base case scenario.
Conclusion: Within the Italian health care system, in patients with CHB, tenofovir is a cost-effective strategy compared with other available therapies. Public health care authorities would benefit from mathematical models designed to estimate the future burden of CHB infection together with the impact of treatment and drug resistance.

Keywords: chronic hepatitis B, Markov model, cost-effectiveness, lamivudine, adefovir, telbivudine, entecavir, tenofovir, pegylated interferon


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Professor Giorgio Colombo

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
A cost-of-illness study of spina bifida in Italy
Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy
An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
Antidiabetic therapy in real practice: indicators for adherence and treatment cost
Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis
Burden of Crohn’s disease: economics and quality of life aspects in Italy
Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation
Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy
Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy
Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
Cost-effectiveness analysis of electrochemotherapy with the Cliniporatorâ„¢ vs other methods for the control and treatment of cutaneous and subcutaneous tumors
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines
Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines
Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
Moderate and severe plaque psoriasis: cost-of-illness study in Italy

Readers of this article also read: